Aldeyra Stock Analysis

ALDX -  USA Stock  

USD 9.07  0.11  1.20%

The current Aldeyra Therapeu price slide could raise concerns from investors as the firm it trading at a share price of 9.07 on 435,600 in volume. The company management teams were unable to exploit market volatilities in June. However, diversifying your overall positions with Aldeyra Therapeu can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.05. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Aldeyra Therapeu partners.
Please continue to Trending Equities.

Search Stock Analysis 

The Aldeyra Therapeu stock analysis report makes it easy to digest most publicly released information about Aldeyra Therapeu and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aldeyra Stock analysis module also helps to analyze the Aldeyra Therapeu price relationship with some important fundamental indicators such as market cap and management efficiency.

Aldeyra Stock Analysis Notes

About 61.0% of the company shares are held by institutions such as insurance companies. The book value of Aldeyra Therapeu was presently reported as 2.65. The company recorded a loss per share of 1.02. Aldeyra Therapeu had not issued any dividends in recent years. Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts. Aldeyra Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. For more info on Aldeyra Therapeu please contact Todd Brady at 781 761 4904 or go to

Aldeyra Therapeu Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aldeyra Therapeu's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aldeyra Therapeu or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aldeyra Therapeu generates negative expected return over the last 90 days
Aldeyra Therapeu has high historical volatility and very poor performance
Net Loss for the year was (38.98 M) with profit before overhead, payroll, taxes, and interest of 0.
Aldeyra Therapeu currently holds about 88.44 M in cash with (35.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.53.
Aldeyra Therapeu has a frail financial position based on the latest SEC disclosures
Roughly 61.0% of the company shares are held by institutions such as insurance companies
Latest headline from Aldeyra Therapeutics shares rise on ADX-2191 FDA orphan drug status - Seeking Alpha

Aldeyra Therapeu Upcoming and Recent Events

Earnings reports are used by Aldeyra Therapeu to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aldeyra Therapeu previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Aldeyra Largest EPS Surprises

Earnings surprises can significantly impact Aldeyra Therapeu's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Aldeyra Therapeu SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Aldeyra Therapeu prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Aldeyra Therapeu investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Aldeyra Therapeu specific information freely available to individual and institutional investors to make a timely investment decision.
9th of June 2021
Submission of Matters to a Vote of Security Holders
6th of May 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
29th of April 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
27th of April 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
21st of April 2021
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
11th of March 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
16th of February 2021
Unclassified Corporate Event
12th of February 2021
Unclassified Corporate Event

Aldeyra Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 529.05 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aldeyra Therapeu's market, we take the total number of its shares issued and multiply it by Aldeyra Therapeu's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Aldeyra Profitablity

Aldeyra Therapeu's profitability indicators refer to fundamental financial ratios that showcase Aldeyra Therapeu's ability to generate income relative to its revenue or operating costs. If, let's say, Aldeyra Therapeu is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aldeyra Therapeu's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aldeyra Therapeu's profitability requires more research than a typical breakdown of Aldeyra Therapeu's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.49) (0.53) 
Return on Average Equity(0.67) (0.68) 
Return on Invested Capital(1.94) (1.99) 

Management Efficiency

The entity has return on total asset (ROA) of (21.31) % which means that it has lost $21.31 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (45.98) %, meaning that it created substantial loss on money invested by shareholders. Aldeyra Therapeu management efficiency ratios could be used to measure how well aldeyra therapeu manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.53 in 2021. Return on Average Equity is likely to drop to -0.68 in 2021. Tangible Assets Book Value per Share is likely to rise to 3.08 in 2021, whereas Total Assets are likely to drop slightly above 67.4 M in 2021.
Last ReportedProjected for 2021
Book Value per Share 1.75  1.89 
Enterprise Value over EBIT(5.00) (5.39) 
Enterprise Value over EBITDA(5.41) (5.84) 
Price to Book Value 4.47  3.91 
Tangible Assets Book Value per Share 2.45  3.08 
Enterprise Value195.1 M164.1 M
Tangible Asset Value83.4 M67.4 M

Technical Drivers

As of the 24th of July, Aldeyra Therapeu shows the risk adjusted performance of (0.031911), and Mean Deviation of 2.67. Aldeyra Therapeu technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Aldeyra Therapeu, which can be compared to its rivals. Please confirm Aldeyra Therapeu standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Aldeyra Therapeu is priced correctly, providing market reflects its regular price of 9.07 per share. Given that Aldeyra Therapeu has jensen alpha of (0.31), we suggest you to validate Aldeyra Therapeu's prevailing market performance to make sure the company can sustain itself at a future point.

Aldeyra Therapeu Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Aldeyra Therapeu Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aldeyra Therapeu insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aldeyra Therapeu's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aldeyra Therapeu insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephen Machatha over a month ago via Macroaxis 
Aldeyra Therapeu exotic insider transaction detected
Perceptive Advisors Llc over two months ago via Macroaxis 
Purchase by Perceptive Advisors Llc of 1200000 shares of Aldeyra Therapeu
Stephen Machatha over three months ago via Macroaxis 
Acquisition by Stephen Machatha of 116201 shares of Aldeyra Therapeu subject to Rule 16b-3
Perceptive Advisors Llc over six months ago via Macroaxis 
Purchase by Perceptive Advisors Llc of 50000 shares of Aldeyra Therapeutics
Stephen Machatha over six months ago via Macroaxis 
Aldeyra Therapeutics exotic insider transaction detected
Perceptive Advisors Llc over a year ago via Macroaxis 
Purchase by Perceptive Advisors Llc of 3200000 shares of Aldeyra Therapeutics
Millerrich Nancy over a year ago via Macroaxis 
Acquisition by Millerrich Nancy of 26503 shares of Aldeyra Therapeutics subject to Rule 16b-3
Joshua Reed over a year ago via Macroaxis 
Acquisition by Joshua Reed of 250000 shares of Aldeyra Therapeutics subject to Rule 16b-3
Perceptive Advisors Llc over a year ago via Macroaxis 
Purchase by Perceptive Advisors Llc of 45100 shares of Aldeyra Therapeutics
Joshua Reed over a year ago via Macroaxis 
Acquisition by Joshua Reed of 250000 shares of Aldeyra Therapeutics subject to Rule 16b-3
Joshua Reed over a year ago via Macroaxis 
Acquisition by Joshua Reed of 137707 shares of Aldeyra Therapeutics subject to Rule 16b-3
Domain Partners Vi Lp over a year ago via Macroaxis 
Payment of 063 shares by Domain Partners Vi Lp of Aldeyra Therapeutics subject to Rule 16b-3

Aldeyra Therapeu Predictive Daily Indicators

Aldeyra Therapeu intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aldeyra Therapeu stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aldeyra Therapeu Forecast Models

Aldeyra Therapeu time-series forecasting models is one of many Aldeyra Therapeu's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aldeyra Therapeu's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Aldeyra Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aldeyra Therapeu stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aldeyra shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Aldeyra Therapeu. By using and applying Aldeyra Stock analysis, traders can create a robust methodology for identifying Aldeyra entry and exit points for their positions.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts. Aldeyra Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.

Current Aldeyra Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aldeyra analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aldeyra analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
25.63Strong Buy8Odds
Aldeyra Therapeu current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aldeyra analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aldeyra stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aldeyra Therapeu, talking to its executives and customers, or listening to Aldeyra conference calls.
Aldeyra Analyst Advice Details

Aldeyra Stock Analysis Indicators

Aldeyra Therapeu stock analysis indicators help investors evaluate how Aldeyra Therapeu stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aldeyra Therapeu shares will generate the highest return on investment. By understating and applying Aldeyra Therapeu stock analysis, traders can identify Aldeyra Therapeu position entry and exit signals to maximize returns.
Quick Ratio7.97
Fifty Two Week Low5.53
Shares Short Prior Month4.81M
Average Daily Volume Last 10 Day851.92k
Average Daily Volume In Three Month2.48M
Shares Percent Shares Out7.41%
Short Percent Of Float8.88%
Forward Price Earnings-8.05
Float Shares46.62M
Fifty Two Week High15.95
Enterprise Value To Ebitda-16.20
Fifty Day Average11.28
Two Hundred Day Average11.61
Please continue to Trending Equities. Note that the Aldeyra Therapeu information on this page should be used as a complementary analysis to other Aldeyra Therapeu's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Aldeyra Stock analysis

When running Aldeyra Therapeu price analysis, check to measure Aldeyra Therapeu's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra Therapeu is operating at the current time. Most of Aldeyra Therapeu's value examination focuses on studying past and present price action to predict the probability of Aldeyra Therapeu's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aldeyra Therapeu's price. Additionally, you may evaluate how the addition of Aldeyra Therapeu to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Transaction History
View history of all your transactions and understand their impact on performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
The market value of Aldeyra Therapeu is measured differently than its book value, which is the value of Aldeyra that is recorded on the company's balance sheet. Investors also form their own opinion of Aldeyra Therapeu's value that differs from its market value or its book value, called intrinsic value, which is Aldeyra Therapeu's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aldeyra Therapeu's market value can be influenced by many factors that don't directly affect Aldeyra Therapeu underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aldeyra Therapeu's value and its price as these two are different measures arrived at by different means. Investors typically determine Aldeyra Therapeu value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aldeyra Therapeu's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.